NCT05361395 2026-03-03
First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Amgen
Phase 1 Active not recruiting
Amgen
Hoffmann-La Roche
BioNTech SE
Phanes Therapeutics
Keythera (Suzhou) Pharmaceuticals Co. Ltd